General
Preferred name
lurasidone
Synonyms
SM-13496 (Hydrochloride) ()
Lurasidone HCl ()
SM-13496 ()
LURASIDONE HYDROCHLORIDE ()
SM-13496 (Hydrochloride)Lurasidone HCl ()
Lurasidone (SM13496) ()
Latuda ()
Lurasidone-d8 ()
P&D ID
PD009198
CAS
367514-88-3
367514-87-2
1132654-54-6
Tags
natural product
drug
available
Approved by
PMDA
FDA
First approval
2010
Drug Status
investigational
approved
Drug indication
Schizophrenia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. ; Bioavailability = 9-19%.
HALF-LIFE 40 mg dose= 18 hours ; 120 mg - 160 mg dose = 29-37 hours
DESCRIPTION Lurasidone is an atypical antipsychotic with activity at serotonin family receptors that are involved in learning and memory. It is devoid of the anticholinergic effects which are common with most other antipsychotics. (GtoPdb)
Compound Sets
20
AdooQ Bioactive Compound Library
A11214
Cayman Chemical Bioactives
9000570
25222
ChEMBL Approved Drugs
CHEMBL1615372
CHEMBL1237021
ChEMBL Drugs
CHEMBL1615372
CHEMBL1237021
Concise Guide to Pharmacology 2017/18
7461
Concise Guide to Pharmacology 2019/20
7461
Concise Guide to Pharmacology 2021/22
7461
Concise Guide to Pharmacology 2023/24
7461
Drug Repurposing Hub
DrugBank
DB08815
DrugBank Approved Drugs
DB08815
DrugCentral
4168
DrugCentral Approved Drugs
4168
DrugMAP
DMCVPXO
DrugMAP Approved Drugs
DMCVPXO
Guide to Pharmacology
7461
NCATS Inxight Approved Drugs
22IC88528T
ReFrame library
Selleckchem Bioactive Compound Library
lurasidone
TargetMol Bioactive Compound Library
T1735
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
492.26
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
7
Aromatic Ring Count
2
cLogP
4.26
TPSA
56.75
Fraction CSP3
0.68
Chiral centers
6.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Target
5-HT1A
5-HT2A
5-HT7
D2
Norepinephrine ??2C
Norepinephrine ¦Á2C
ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7
5-HT Receptor,Dopamine Receptor
MOA
5-HT Receptor antagonist
dopamine receptor inhibitor
Norepinephrine inhibitor
dopamine receptor antagonist, serotonin receptor antagonist
Indication
schizophrenia
Source data